MARTINOVICH ROBERT F 4

What Happened

• Robert F. Martinovich, a director of Core Laboratories, reported restricted shares vesting and the conversion/exercise of derivative awards on April 1, 2026. Specifically, 7,895 restricted shares were recorded as an award/acquisition (A) at $0.00 (vested), and two derivative conversion/exercise (M) entries show 8,069 shares acquired at $0.00 and a matching 8,069 shares disposed at $0.00. No cash amounts are reported for these transactions.

Key Details

• Transaction date: April 1, 2026; Form 4 filed: April 7, 2026 (filed after the transaction date).
• Reported prices: $0.00 per share for all entries (typical for vesting/conversion reporting).
• Shares acquired: 7,895 (award/vested) and 8,069 (conversion/exercise); Shares disposed: 8,069 (conversion/disposition).
• Shares owned after transaction: not specified in the provided excerpt of the filing.
• Footnotes:
  • F2: The 7,895 Restricted Shares vested at the end of a one‑year vesting period on April 1, 2026.
  • F1: Certain Restricted Shares referenced will vest on April 1, 2027 and are subject to a deferral election and post‑separation distribution rules.
• Timeliness: The Form 4 was filed six days after the transaction date; this is later than the usual two‑business‑day reporting window and is therefore late.

Context

• The $0.00 price and the nature of the entries indicate these were vesting and internal conversions/exercises of awards rather than open‑market purchases or cash sales. The matching acquisition and disposition of 8,069 derivative shares on the same date suggests a conversion/transfer event rather than a standard brokerage sale (the filing does not specify the reason for the disposition).
• For retail investors: these entries reflect compensation-related equity activity (vesting/conversion) by a director, not an outright open‑market purchase that would more directly signal a personal bullish bet.